Blocking P300 HAT activity reverses the epigenetic changes and vascular-like phenotype conversion and reduces tumor growth post-treatment, highlighting its potential as a therapeutic vulnerability for preventing GBM relapse. Here, TMPRSS11D is linked to neoplasm.